Advertisement

PharmacoEconomics

, Volume 32, Issue 3, pp 245–255 | Cite as

Does Economic Incentive Matter for Rational Use of Medicine? China’s Experience from the Essential Medicines Program

  • Mingsheng Chen
  • Lijie Wang
  • Wen ChenEmail author
  • Luying Zhang
  • Hongli Jiang
  • Wenhui Mao
Original Research Article

Abstract

Background

Before the new round of healthcare reform in China, primary healthcare providers could obtain a fixed 15 % or greater mark-up of profits by prescribing and selling medicines. There were concerns that this perverse incentive was a key cause of irrational medicine use. China’s new Essential Medicines Program (EMP) was launched in 2009 as part of the national health sector reform initiatives. One of its core policies was to eliminate primary care providers’ economic incentives to overprescribe or prescribe unnecessarily expensive drugs, which were regarded as consequences of China’s traditional financing system for health institutions.

Objectives

The objective of the study was to measure changes in prescribing patterns in primary healthcare facilities after the removal of the economic incentives for physicians to overprescribe as a result of the implementation of the EMP.

Methods

A comparison design was applied to 8,258 prescriptions in 2007 and 8,278 prescriptions in 2010, from 83 primary healthcare facilities nationwide. Indicators were adopted to evaluate medicine utilization, which included overall number of medicines, average number of Western and traditional Chinese medicines, pharmaceutical expenditure per outpatient prescription, and proportion of prescriptions that contained two or more antibiotics. We further assessed the use of medicines (antibiotics, infusion, hormones, and intravenous injection) per disease-specific prescription for hypertension, diabetes, coronary artery heart disease, bronchitis, upper respiratory tract infection, and gastritis. A difference-in-difference analysis was employed to evaluate the net policy effect.

Results

Overall changes in indicators were not found to be statistically significant between the 2 years. The results varied for different diseases. The number of Western drugs per outpatient prescription decreased while that of traditional Chinese medicines increased. Overuse of antibiotics remained an extensive problem in the treatment of many diseases, though there was some significant improvement in certain diseases, like diabetes in rural areas. Medicine expenditure per prescription also decreased.

Conclusions

It seems that the removal of a perverse economic incentive alone would not lead to improvement of healthcare providers’ prescribing patterns. The rationality of the Essential Medicines List and the lack of payers’ and providers’ meaningful involvement in the development of the policy possibly contribute to the lack of significant changes in prescribing behaviors. It is suggested that China should adopt more comprehensive policies for healthcare facilities, physicians, patients, and payers, rather than just relying on economic incentives to improve rational use of medicines.

Keywords

Essential Medicine Rational Medicine Primary Healthcare Facility Outpatient Prescription Essential Medicine List 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

The authors, Wen Chen, Mingsheng Chen, Lijie Wang, Luying Zhang, Hongli Jiang, and Wenhui Mao, declare that they have no competing interests. The Ministry of Health of the People’s Republic of China funded the study and allowed the use of the data for academic research. The sponsor had no influence on the study design, collection, analysis, and interpretation of the data and the writing of the manuscript. We thank the Health Departments of the provinces and local health bureaus for their cooperation and for facilitating field data collection.

Prof. Wen Chen was the principal investigator of this study. He was in charge of the overall study design, data collection, analysis, and interpretation. Mingsheng Chen contributed to the study design, data analysis, and writing of the first draft of the manuscript. Lijie Wang contributed to the study design, helped with data analysis and modified the manuscript. Luying Zhang conducted the data collection and reviewed and polished the manuscript. Hongli Jiang conducted the data collection and reviewed the manuscript. Wenhui Mao participated in data collection and analysis.

References

  1. 1.
    Jassim Al Khaja KA, Sequeira RP, Mathur VS. Patterns of utilization of antihypertensive drug combinations in Bahrain: do they conform with international guidelines? Int J Clin Pharmacol Ther. 2000;38(12):568–80.Google Scholar
  2. 2.
    World Health Organization. Medicines use in primary care in developing and transitional countries: fact book summarizing results from studies reported between 1990 and 2006. Geneva: WHO; 2009.Google Scholar
  3. 3.
    Shivhare SC, Kunjwani HK, Manikrao AM, et al. Drugs hazards and rational use of drugs: a review. J Chem Pharm Res. 2010;2(1):106–12.Google Scholar
  4. 4.
    International Prescrire. A review of new drugs and indications in 2002: Financial speculation or better patient care? Prescrire Int. 2003;12:74–7.Google Scholar
  5. 5.
    Sara B, Jonathan DQ, Germán V. Public-private roles in the pharmaceutical sector: Implications for equitable access and rational drug use. Geneva: WHO; 1997.Google Scholar
  6. 6.
    World Health Organization. Promoting rational use of medicines: core components. In: WHO policy perspectives on medicines. Report no. 5. Geneva: WHO; 2002.Google Scholar
  7. 7.
    Hsiao WC. The political economy of Chinese health system reform. Health Econ Policy Law. 2007;2(Pt 3):241–9.PubMedCrossRefGoogle Scholar
  8. 8.
    China National Health Economics Institute. China national health accounts report 2009. Beijing: Ministry of Health; 2009.Google Scholar
  9. 9.
    Hu S, Chen W, Cheng X, et al. Pharmaceutical cost-containment policy: experiences in Shanghai, China. Health Policy Plan. 2001;16(Suppl. 2):4–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Chen Y, Schweitzer SO. Issues in drug pricing, reimbursement, and access in China with references to other Asia-Pacific Region. Value in Health. 2008;11(Suppl. 1):124–9.CrossRefGoogle Scholar
  11. 11.
    Yang L. The essential medicine system in China: strategies and challenges (abstract). Value Health. 2010;533.Google Scholar
  12. 12.
    Ho LS. Market reform and China’s health care system. Soc Sci Med. 1995;41(8):1065–72.PubMedCrossRefGoogle Scholar
  13. 13.
    Jiang Qian, Nancy Yu B, Ying G, et al. Outpatient prescription practices in rural township health centers in Sichuan province, China. BMC Health Serv Res. 2012;12(1):324.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Liang Xiaoyun, Jin Chenggang, Wang Li, et al. Unnecessary use of antibiotics for inpatient children with pneumonia in two counties of rural China. Int J Clin Pharm. 2011;33(5):750–4.PubMedCrossRefGoogle Scholar
  15. 15.
    Eggleston K, Ling L, Qingyue M, et al. Health service delivery in China: a literature review. Health Econ. 2008;17(2):149–65.PubMedCrossRefGoogle Scholar
  16. 16.
    Yu X, Li C, Shi Y, et al. Pharmaceutical supply chain in China: current issues and implications for health system reform. Health Policy. 2010;97(1):8–15.PubMedCrossRefGoogle Scholar
  17. 17.
    Chen W, Tang SL, Sun J, et al. Availability and use of essential medicines in China: manufacturing, supply, and prescribing in Shandong and Gansu provinces. BMC Health Serv Res. 2010;10:211–8.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Sun X, Jackson S, Carmichael GA, Sleigh AC. Prescribing behaviour of village doctors under China’s New Cooperative Medical Scheme. Soc Sci Med. 2009;68:1775–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Yip W, Hsiao WC. Market watch: the Chinese health system at a crossroads. Health Affairs. 2008;27:460–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Yao KH, Yang YH. Streptococcus pneumonia diseases in Chinese children: past, present and future. Vaccine. 2008;26(35):4425–33.PubMedCrossRefGoogle Scholar
  21. 21.
    Li J, Ma Y, Wang Z, et al. Klebsiella pneumonia: epidemiology and analysis of risk factors for infections caused by resistant strains. Chin Med J. 2002;115(8):1158–62.PubMedGoogle Scholar
  22. 22.
    Dong L, Yan H, Wang D. Antibiotic prescribing patterns in village health clinics across 10 provinces of Western China. J Antimicrob Chemother. 2008;62(2):410–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Dong L, Yan H, Wang D. Drug prescribing indicators in village health clinics across 10 provinces of Western China. Fam Pract. 2011;28(1):63–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Chen Z. Launch of the health-care reform plan in China. Lancet. 2009;373:1322–4.PubMedCrossRefGoogle Scholar
  25. 25.
    Li Q, Zeng FD. The necessity to develop the national drug policy in our country (in Chinese). Chin J Pharmaco Epidemiol. 2003;12(6):281–5.Google Scholar
  26. 26.
    International Network for Rational Use of Drugs. How to investigate drug use in health facilities: selected drug use indicators. Geneva: WHO; 1993.Google Scholar
  27. 27.
    Meng Q, Xu L, Zhang YG, et al. Trends in access to health services and financial protection in China between 2003 and 2011: a cross-sectional study. Lancet. 2012;379(9818):805–14.PubMedCrossRefGoogle Scholar
  28. 28.
    Babiarz KS, Miller G, Yi H, et al. New evidence on the impact of China’s New Rural Cooperative Medical Scheme and its implications for rural primary healthcare: multivariate difference-in-difference analysis. BMJ. 2010;341:1–9.CrossRefGoogle Scholar
  29. 29.
    Couper MC, Mehta D. WHO model formulary. Geneva: WHO; 2002.Google Scholar
  30. 30.
    Ministry of Health China. Prescription Administrative Policy, 2007 (online). http://www.gov.cn/flfg/2007-03/13/content_549406.htm. Accessed 9 Dec 2012.
  31. 31.
    Carandang ED. Rational drug use: Philippine experience. In: Chaudhury RR, Somrongthorn, editors. International experience in rational use of drugs. Bangkok: The College of Public Health, Chulalongkorn University; 1999.Google Scholar
  32. 32.
    Chetley A, Rohde JE. National drug policies as the first step towards rational drug use: the experience of Bangladesh. In: Chaudhury RR, editors. International experience in rational use of drugs. Bangkok: The College of Public Health, Chulalongkorn University; 1994.Google Scholar
  33. 33.
    Chaudhury RR, Parameswar R, Gupta U, et al. Quality medicines for the poor: experience of the Delhi programme on rational use of drugs. Health Policy Plan. 2005;20(2):124–36.PubMedCrossRefGoogle Scholar
  34. 34.
    World Health Organization. Promoting rational use of medicines: core components. Geneva: WHO; 2002.Google Scholar
  35. 35.
    Bank World. Financing, pricing, and utilization of pharmaceuticals in China: the road to reform. Washington, DC: World Bank; 2010.Google Scholar
  36. 36.
    Figueiras A, Sastre I, Gestal-Otero JJ. Effectiveness of educational interventions on the improvement of drug prescription in primary care: a critical literature review. J Eval Clin Pract. 2001;7(2):223–41.PubMedCrossRefGoogle Scholar
  37. 37.
    Mandal SC, Mandal M. Improving use of medicines in the community through interventions. Value Health. 2011;14(7):A340.CrossRefGoogle Scholar
  38. 38.
    Chakraborty A, Roy S, Loeffler J, Chaves RL. Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection. J Antimicrob Chemother. 2009;64(1):151–8.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  • Mingsheng Chen
    • 1
  • Lijie Wang
    • 1
  • Wen Chen
    • 1
    Email author
  • Luying Zhang
    • 1
  • Hongli Jiang
    • 1
  • Wenhui Mao
    • 1
  1. 1.Department of Health Economics, School of Public HealthFudan UniversityShanghaiPeople’s Republic of China

Personalised recommendations